TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. The Department of Pharmaceuticals has amended the UCMPMD 2024, clarifying valuation of free evaluation samples at stockist price if self-manufactured or average purchase price if sourced externally. Companies in multiple associations may submit disclosures through one, with prior intimation to others and notification to the Department when switching.
Source: short-link.me/18ym-

2. India’s Health Ministry has proposed amendments to the New Drugs and Clinical Trials Rules, 2019, enabling simplified approval for bioavailability and bioequivalence (BA/BE) studies of oral drugs approved in India or select countries, for export purposes. The draft exempts certain drug categories and caps sample size at 48. Stakeholders may submit objections or suggestions by 27 September 2025.
Source: short-link.me/1d3UX

3. Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organization (CDSCO) have released draft protocols for evaluating In-Vitro Diagnostics (IVDs) for tuberculosis, including drug-resistant strains. Stakeholders can submit comments by September 7, 2025. Final protocols will be based on this feedback before final clearance is given by ICMR and CDSCO.
Source: short-link.me/18ylZ

4. India’s Punjab and Haryana High Court has ruled that legible medical prescriptions is a fundamental right of patients and doctors must write prescriptions in capital letters until Digitalization. PGIMER Chandigarh’s “Doctor Desk” e-prescription system is expected to be implemented within two years.
Source: short-link.me/18ym7

5. The Ministry of Health and Family Welfare has issued draft amendments to the New Drugs and Clinical Trials Rules, 2019. The proposals reduce approval timelines from ninety to forty-five working days and introduce a simplified notification system for manufacturing certain drugs meant for analytical and preclinical testing.
Source: short-link.me/1d3Vg

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. India’s Food authority (FSSAI) has extended the validity of No Objection Certificates (NOCs) granted to imported alcoholic beverages bottled at origin or in bulk with over 10% alcohol content and with no expiry date to 365 days. If consignments remain in Customs premises beyond this period, re-validation can be done through visual inspection upon payment of a prescribed fee.
Source: bit.ly/44Lgsvu

2. India’s Drugs Consultative Committee (DCC) has reportedly proposed enabling the licensing of Bedaquiline, Delamanid, Pretomanid, and Rifapentine only through India’s National Tuberculosis Elimination Programme (NTEP), with strict label warnings. This move aims to prevent misuse, preserve drug effectiveness, and combat rising cases of drug resistant tuberculosis.
Source: bit.ly/4km2dC7

3. The National for Allied and Healthcare Professions (NCAHP) has recommended replacing the term “Paramedical” with “Allied and Healthcare” across all government and institutional communications (verbal, written or electronic). States, UTs, and relevant bodies must implement and enforce this updated terminology in all official usage.
Source: bit.ly/4ltTcYA

4. A popular U.S. snack brand will remove “100% natural” claims from its packaging after lawsuits highlighted trace herbicide residues in its ingredients. Although levels were within legal limits, consumer groups argued the label was misleading.
Source: bit.ly/3TlDeE4

5. The U.S. Food and Drug Administration (FDA) has issued warning letters to four entities, including an Indian drug manufacturer, citing violations such as non-compliance to clinical trial protocol, insanitary conditions, contamination risks, and inadequate donor screening. The FDA has directed them to implement corrective actions to ensure compliance and safeguard product quality.
Source: bit.ly/44aoWw8
Source: bit.ly/45S8eD4
Source: bit.ly/4nqNn01
Source: bit.ly/45Sv11E

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The District Consumer Disputes Redressal Commission in Hyderabad has ordered a compensation of Rs. 10 lakh to a patient after cardiologists at a local hospital made the patient undergo multiple procedures in one go without understanding the need for multiple procedures, and failed to follow standard protocols during treatment. The commission determined that the doctor’s negligence led to significant complications, proving a deficiency of service which was against patient safety and care.
Source: bit.ly/3VufMps

2. The National Medical Commission (NMC) has released comprehensive guidelines to identify and prevent the admission of fake patients in medical colleges, a practice that undermines patient care and ethical standards. The guidelines highlight red flags such as unusually high admissions on inspection days, absence of significant medical conditions, and lack of necessary investigations. Institutions found engaging in this unethical practice may face stringent penalties, including hefty fines and restrictions on student admissions.
Source: bit.ly/4iDw5ua

3. India is set to introduce “nafithromycin”, the first indigenous macrolide antibiotic, pending final approval from the Central Drugs Standard Control Organization (CDSCO). This innovative antibiotic, which is ten times more effective than azithromycin, offers a rapid three-day treatment for community-acquired bacterial pneumonia caused by drug-resistant bacteria, marking a significant advancement in the fight against antimicrobial resistance (AMR).
Source: bit.ly/4f4vuP6

4. The Indian government is intensifying efforts to eliminate tuberculosis (TB) by 2025, targeting 347 high-focus districts across 33 states and Union territories. A 100-day TB elimination campaign will be launched by the Union Health ministry in this regard to enhance case detection, reduce diagnostic delays, and improve treatment outcomes, particularly among high-risk groups.
Source: bit.ly/49qNnXb

5. The USFDA is considering a ban on Red 3, a synthetic food dye linked to potential health risks, including cancer and behavioural issues in children. This decision follows increasing public pressure and legislative actions in several states, including California, which has already prohibited the dye in food products. The FDA aims to act on a petition to revoke Red 3’s authorization in the coming weeks, reflecting growing concerns over food safety standards in the U.S.
Source: bit.ly/3Vvxed0